Sulfasalazine Dosage

Regular Adult Dose for Ulcerative Colitis

3 to 4 g/day orally in doses that are equally divided

  • To lessen potential GI intolerance, a lower starting dose (e.g., 1 or 2 g/day) might be regarded.
  • Symptoms could be decreased by halving the daily dosage and then improving it slowly over several times, if GI intolerance happens after the initial couple of doses
  • The drug needs to be discontinued for 5 to 7 times subsequently restarted in a a lower dose if intolerance goes on.
  • If over 4 4 g/day is required to achieve desired therapeutic result toxicity hazard is highly recommended.
  • Samples, sigmoidoscopy, and clinical standards needs to be assessed to ascertain result of ulcerative colitis to drug treatment.
  • When endoscopy confirms sufficient enhancement, dose needs to be lowered to maintenance amount. Dose needs to be raised to amounts that were formerly successful if diarrhea recurs.

Common Adult Dose for Rheumatoid Arthritis

Delayed-release tablets: 1000 milligrams orally twice a day

Dosing regimen that is implied:
Week 1: 500 mg orally once a day in the evening
Week 2: 500 mg orally twice a day (morning and evening)
Week 3: 1000 mg in the evening and 500 milligrams orally each day
Week 4: 1000 milligrams orally two times a day (morning and evening)
  • To lessen potential GI intolerance, a lower starting dose (e.g., 0.5 to 1 g/day) is recommended; a suggested dosing program is supplied above.
  • Level of progress in extent as well as amount of joints may be assessed to ascertain effectiveness of drug treatment.
  • This drug doesn’t generate an instant reaction. Concomitant analgesics and/or nonsteroidal anti-inflammatory drugs are advocated (at least until the result of the drug is obvious).
  • Remedial result was found 4 weeks after beginning treatment; 1-2 months of treatment might be required before clinical advantage is found.

Regular Adult Dose for Crohn’s Disease

3 to 6 grams/day orally in divided doses

This dose was recommended for light to moderate colonic or active ileocolonic disorder.
Care gains haven’t been consistent after medical inductive treatment.

Common Adult Dose for Uveitis

Study (number=10) – Acute anterior recurrent uveitis

Initial dose: 500 mg/day, then increased by 500 mg/week

Maintenance dose: 1 g twice a day for 1 year

In cases of new flare, dose was increased by 500 mg/week up to 3 g/day

Common Pediatric Dose for Ulcerative Colitis

6 years or older

Initial therapy:40 to 60 mg/kg/ day
Care therapy: 30 mg/kg/ day
  • Symptoms could be reduced by halving the daily dose and then improving it slowly over several days, if GI intolerance happens after the initial couple of doses.
  • The drug needs to be discontinued for 5 to 7 days subsequently restarted in a reduced daily dose if intolerance goes on.
  • Sigmoidoscopy clinical standards, and biopsy samples needs to be assessed to ascertain result of acute ulcerative colitis to drug treatment.
  • When endoscopy confirms sufficient enhancement, dose needs to be reduced to maintenance amount.
  • Dose needs to be raised to amounts that were formerly successful if diarrhea recurs.
  • Drug treatment frequently must be continued, even when clinical symptoms are restrained.
    Uses:

  • In the treatment of mild to moderate ulcerative colitis.
  • As adjunctive therapy in severe ulcerative colitis.
  • To prolong the remission period between acute attacks of ulcerative colitis.

Regular Pediatric Dose for Juvenile Rheumatoid Arthritis

Delayed-release tablets:

6 years or older

Initial therapy:30 to 50 mg/kg/day orally in 2 divided doses
Maximum dose:2 g/day (usually)

Dosing needs to be began maintenance dose and increased weekly until maintenance dose is reached at 1 month. To reduce potential GI intolerance. In treating patients with polyarticular-course juvenile rheumatoid arthritis who reacted inadequately to other NSAIDs or salicylates.

Precautions

Effectiveness and security haven’t been created in ulcerative colitis patients younger than 24 months. Effectiveness and security haven’t been created in polyarticular-course juvenile rheumatoid arthritis patients younger. This drug isn’t recommended for treating systemic-course juvenile rheumatoid arthritis symptoms.